All Photos(1)

Documents

COO/COA

1000420

USP

Abacavir Related Compound A

Name: Abacavir Related Compound A
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(1S,4R)-4-[2,6-Diamino-9H-purin-9-yl]-2-cyclopentene-1-methanol

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₁H₁₄N₆O

CAS Number:

124752-25-6

Molecular Weight:

246.27

UNSPSC Code:

41116107

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

abacavir

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C11H14N6O/c12-9-8-10(16-11(13)15-9)17(5-14-8)7-2-1-6(3-7)4-18/h1-2,5-7,18H,3-4H2,(H4,12,13,15,16)/t6-,7+/m1/s1

InChI key

ZKJUXHDSLJYKED-RQJHMYQMSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Abacavir Related Compound A USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1000485

1000441

1000452

PHR1256

Abacavir sulfate, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001561

Abacavir sulfate, European Pharmacopoeia (EP) Reference Standard

Y0001551

Abacavir for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001552

Abacavir for peak identification, European Pharmacopoeia (EP) Reference Standard

1000437

BP1112

Abacavir sulfate, British Pharmacopoeia (BP) Reference Standard

BP1113

Abacavir impurity standard, British Pharmacopoeia (BP) Reference Standard

BP1114

Abacavir Impurity 1, British Pharmacopoeia (BP) Reference Standard

PHR2074

Abacavir Impurity F, pharmaceutical secondary standard, certified reference material

Pictograms

GHS05

Signal Word

Danger

Hazard Statements

H318

Precautionary Statements

P280 - P305 + P351 + P338

Hazard Classifications

Eye Dam. 1

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Evaluation of gastrointestinal absorption and metabolism.

C L Zimmerman et al.

Drug metabolism reviews, 29(4), 957-975 (1998-01-09)

Comparative brain exposure to (-)-carbovir after (-)-carbovir or (-)-6-aminocarbovir intravenous infusion in rats.

Y D Wen et al.

Pharmaceutical research, 12(6), 911-915 (1995-06-01)

Evaluate the ability of (-)-6-aminocarbovir ((-)-6AC) to improve the CNS exposure to (-)-carbovir ((-)-CBV). Activation of (-)-6AC in vitro was assessed by incubations of rat brain tissue homogenates. The in vivo brain exposure to (-)-CBV was then examined in rats

First-pass disposition of (-)-6-aminocarbovir in rats. I. Prodrug activation may be limited by access to enzyme.

Y Wen et al.

Drug metabolism and disposition: the biological fate of chemicals, 27(1), 113-121 (1999-01-12)

Several in vitro and in situ approaches were used to determine the dominant presystemic activation site for (-)-6-aminocarbovir, (-)-carbocyclic 2',3'-didehydro-2', 3'-dideoxy-6-deoxy-6-aminoguanosine (6AC) conversion in rats. The in vitro disappearance half-lives (mean +/- S.D.) in the cytosolic fractions obtained from homogenates

(-)-6-Aminocarbovir pharmacokinetics and relative carbovir exposure in rats.

R L Yeager et al.

Drug metabolism and disposition: the biological fate of chemicals, 19(2), 462-466 (1991-03-01)

The potential for the metabolic conversion of (-)-6-aminocarbovir to (-)-carbovir, a potent reverse transcriptase inhibitor effective against human immunodeficiency virus, has been examined in male Sprague-Dawley rats. Plasma (-)-6-aminocarbovir concentrations declined rapidly in a biphasic manner following an iv bolus

Lack of effect of catheterization on the pharmacokinetics of (-)-carbovir in rats.